Chakraborty, Samik
Balan, Murugabaskar
Flynn, Evelyn
Zurakowski, David
Choueiri, Toni K.
Pal, Soumitro
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA193675, R01 CA222355)
Article History
Received: 7 August 2018
Revised: 9 December 2018
Accepted: 20 December 2018
First Online: 15 January 2019
Conflict of interest
: <b>Disclosures for Dr. Choueiri:</b> Research (Institutional and personal): AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Takeda. Honoraria: AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics. Consulting or Advisory Role: AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group. No speaker’s bureau. No leadership or employment in for-profit companies. No Patents, royalties or other intellectual properties. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies potentially involved in research around the subject matter. <b>Disclosures for Other Authors:</b> Other authors declare no potential conflict of interest.